Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Effect of Kale Consumption on Human Xenobiotic Metabolizing Enzymes

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Nuoroda įrašoma į mainų sritį
StatusasBaigta
Rėmėjai
USDA Beltsville Human Nutrition Research Center

Raktažodžiai

Santrauka

The primary objective of this study is to determine how daily consumption of kale changes the activity of human xenobiotic metabolizing enzymes. Secondary objectives are to measure absorption and metabolism of kale phytonutrients, and to determine how kale consumption affects gene expression related to metabolism and lipid measures associated with cardiovascular health.

apibūdinimas

Consumption of Brassica vegetables (which include broccoli, cabbage, and kale) is inversely associated with the incidence of several cancers, including cancers of the lung, stomach, liver, colon, rectum, breast, endometrium, and ovaries. Brassica vegetables are a good source of many nutrients, but the unique characteristic of Brassicas is their rich content of glucosinolates. Glucosinolates are sulfur-containing compounds that are converted to bioactive metabolites by a plant enzyme called myrosinase, which is released when the vesicles containing myrosinase are ruptured by chewing or cutting. These bioactive compounds are considered to be the active agent for cancer prevention. Their ability to reduce risk of cancer may derive in part from their ability to modulate foreign-substance metabolizing enzymes, which include enzymes called Phase I cytochrome P450s and Phase II enzymes.

The primary aim of this study is to investigate how daily consumption of kale influences foreign-substance metabolizing enzymes, which in turn may reduce cancer risk. Secondary aims of this study include measuring metabolism of kale nutrients, effect of kale consumption on fecal microbiota, and how kale consumption influences risk factors for cardiovascular disease.

Datos

Paskutinį kartą patikrinta: 08/31/2018
Pirmasis pateikimas: 02/21/2018
Numatytas registravimas pateiktas: 02/21/2018
Pirmas paskelbtas: 02/27/2018
Paskutinis atnaujinimas pateiktas: 09/10/2018
Paskutinis atnaujinimas paskelbtas: 09/11/2018
Faktinė studijų pradžios data: 04/17/2018
Numatoma pirminio užbaigimo data: 07/31/2018
Numatoma studijų užbaigimo data: 07/31/2018

Būklė ar liga

Healthy Volunteers

Intervencija / gydymas

Other: Base diet

Other: Kale Treatment

Fazė

-

Rankų grupės

RankaIntervencija / gydymas
Other: Base diet
Subjects will consume a base diet prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
Other: Base diet
Base Diet
Other: Kale Treatment
Subjects will consume 500 g of kale per 2000 kcal of food, split between breakfast and dinner, as a supplement to the base diet.
Other: Kale Treatment
Base Diet plus Kale

Tinkamumo kriterijai

Amžius, tinkami studijuoti 21 Years Į 21 Years
Tinkamos studijoms lytysAll
Priima sveikus savanoriusTaip
Kriterijai

Inclusion Criteria:

- 5 years cancer free

- Not a tobacco product user

- Blood glucose less than 126 mg/dL

- Able to voluntarily agree to participate and sign an informed consent document

Exclusion Criteria:

- Brassica vegetable allergy or intolerance

- use of oral contraceptives

- Women who have given birth in the previous 12 months

- Type 2 diabetes requiring the use of diabetes pills, insulin, or non-insulin shots

- Use of blood-thinning medications such as Coumadin (warfarin), Dicumarol, or Miradon (anisindione)

- History of bariatric surgery or nutrient malabsorption disease

- Pregnant, lactating, or intending to become pregnant during the study period

- Crohn's disease or diverticulitis

- Suspected or known strictures, fistulas or physiological/mechanical GI obstruction

- Self-report of alcohol or substance abuse within the past 12 months and/or current acute treatment or rehabilitation program for these problems (long-term participation in Alcoholics Anonymous is not an exclusion)

Rezultatas

Pirminės rezultatų priemonės

1. CYP1A2 activity will be analyzed [Day 7]

Plasma will be analyzed for caffeine metabolite ratios

2. CYP1A2 activity will be analyzed [Day 14]

Plasma will be analyzed for caffeine metabolite ratios

3. CYP1A2 activity will be analyzed [Day 42]

Plasma will be analyzed for caffeine metabolite ratios

4. CYP1A2 activity will be analyzed [Day 49]

Plasma will be analyzed for caffeine metabolite ratios.

Antrinės rezultatų priemonės

1. The ability of fecal microbiota to metabolize glucosinolates will be determined [Days 14 and 49.]

Fecal samples will be presented with glucosinolates to determine the change in the ability of fecal microbes to metabolize the glucosinolates.

2. Metabolites of Kale [On days 35 and 36]

Metabolites of Kale will be measured in plasma and urine.

3. Fecal microbiota will be analyzed for microbial DNA [Days 0, 14, 35, and 49]

Fecal microbial communities will be determined using DNA extracted from fecal samples.

4. UGT1A1 activity will be analyzed [On days 7, 14, 42, and 49]

Serum will be analyzed for bilirubin concentration to assess UGT1A1 activity

5. Glutathione S-transferase alpha concentration [On days 7, 14, 42, and 49]

Glutathione S-transferase alpha concentration will be measured in serum

6. Total cholesterol [On days 0, 7, 14, 35, 42, and 49]

Total cholesterol will be measured in serum

7. LDL cholesterol [On days 0, 7, 14, 35, 42, and 49]

LDL cholesterol will be measured in serum

8. HDL cholesterol [On days 0, 7, 14, 35, 42, and 49]

HDL cholesterol will be measured in serum

9. Triacylglycerides [On days 0, 7, 14, 35, 42, and 49]

Triacylglycerides will be measured in serum

10. Apolipoprotein A1 [On days 0, 7, 14, 35, 42, and 49]

Apolipoprotein A1 will be measured in serum

11. Apolipoprotein A2 [On days 0, 7, 14, 35, 42, and 49]

Apolipoprotein A2 will be measured in serum

12. Apolipoprotein B [On days 0, 7, 14, 35, 42, and 49]

Apolipoprotein B will be measured in serum

13. Changes in gene expression [On days 0, 14, 35, and 49]

messenger RNA concentrations in whole blood will be measured

Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge